253 related articles for article (PubMed ID: 28393006)
1. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.
Imakita T; Fujita K; Kanai O; Terashima T; Mio T
Respir Med Case Rep; 2017; 21():52-55. PubMed ID: 28393006
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
3. Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases.
Liu H; Chen LH; Zhang ZH; Wang N; Zhuang SH; Chen H; Du J; Pang LJ; Qi Y
Front Oncol; 2022; 12():1022705. PubMed ID: 36439460
[TBL] [Abstract][Full Text] [Related]
4. Transformation of Lung Squamous Cell Carcinoma to Small Cell Lung Cancer After Immunotherapy Resistance: A Case Report.
Wang D; Ye W; Chen D; Shi Q; Ma D
Cancer Manag Res; 2023; 15():803-808. PubMed ID: 37583652
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases.
Shen Q; Qu J; Sheng L; Gao Q; Zhou J
Front Oncol; 2021; 11():619371. PubMed ID: 34094904
[TBL] [Abstract][Full Text] [Related]
6. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
Tokaca N; Wotherspoon A; Nicholson AG; Fotiadis N; Thompson L; Popat S
Lung Cancer; 2017 Sep; 111():65-68. PubMed ID: 28838401
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
8. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation.
Abdallah N; Nagasaka M; Abdulfatah E; Shi D; Wozniak AJ; Sukari A
Lung Cancer (Auckl); 2018; 9():85-90. PubMed ID: 30498383
[TBL] [Abstract][Full Text] [Related]
9. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
[TBL] [Abstract][Full Text] [Related]
10. Abscopal effect of radiation therapy and nivolumab in a patient with combined small-cell lung cancer: a case report.
Wang W; Li L; Wu S; Shen J; Huang C; Chen Y; Li S
Immunotherapy; 2022 Aug; 14(12):909-914. PubMed ID: 35787148
[TBL] [Abstract][Full Text] [Related]
11. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
13. Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report.
Higuchi M; Kawamata T; Oshibe I; Soeta N; Saito T; Hojo H; Matsumura Y; Suzuki H
Case Rep Oncol; 2021; 14(2):1124-1133. PubMed ID: 34413743
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
15. Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report.
Nishikawa K; Okuma Y; Hashimoto K; Kashima J
Tohoku J Exp Med; 2019 Apr; 247(4):247-250. PubMed ID: 30996212
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.
Rittberg R; Banerji S; Green S; Qing G; Dawe DE
Cureus; 2020 Oct; 12(10):e11224. PubMed ID: 33269152
[TBL] [Abstract][Full Text] [Related]
17. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
19. Combined small cell lung carcinoma and giant cell carcinoma: a case report.
Saito T; Tsuta K; Fukumoto KJ; Matsui H; Konobu T; Torii Y; Yokoi T; Kurata T; Kurokawa H; Uemura Y; Saito Y; Murakawa T
Surg Case Rep; 2017 Dec; 3(1):52. PubMed ID: 28364180
[TBL] [Abstract][Full Text] [Related]
20. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
